{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:19:35Z","timestamp":1792513175944,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005687","name":"University of Frankfurt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.euf.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T01:31:53Z","timestamp":1618363913000},"page":"399-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-0889","authenticated-orcid":false,"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"W\u00fcrnschimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Nocera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Coll\u00e0 Ruvolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2021.04.003_bib0005","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0010","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2017.10.002","article-title":"Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-na\u00efve prostate cancer: a systematic review and network meta-analysis","volume":"73","author":"Wallis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.04.003_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41391-018-0055-8","article-title":"Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis","volume":"21","author":"Tan","year":"2018","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2021.04.003_bib0020","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JU.0000000000000636","article-title":"New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis","volume":"203","author":"Marchioni","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.04.003_bib0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/PPO.0000000000000418","article-title":"Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape","volume":"26","author":"Kinsey","year":"2020","journal-title":"Cancer J"},{"key":"10.1016\/j.euf.2021.04.003_bib0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","article-title":"Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"77","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.04.003_bib0035","article-title":"Comparison of current systemic combination therapies for metastatic hormone-sensitive prostate cancer and selection of candidates for optimal treatment: a systematic review and Bayesian network meta-analysis","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0040","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/cncr.32039","article-title":"Metastatic castration-sensitive prostate cancer: abiraterone, docetaxel, or\u2026","volume":"125","author":"Barata","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2021.04.003_bib0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41391-017-0014-9","article-title":"The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation","volume":"21","author":"McNamara","year":"2018","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2021.04.003_bib0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/03007995.2018.1447450","article-title":"Abiraterone acetate\/androgen deprivation therapy combination versus docetaxel\/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy","volume":"34","author":"Kassem","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.euf.2021.04.003_bib0055","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.2217\/fon-2017-0445","article-title":"The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?","volume":"13","author":"Aoun","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0060","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2021.04.003_bib0065","doi-asserted-by":"crossref","unstructured":"Preisser F, Chun FKH, Banek S, et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate Int. In press. https:\/\/doi.org\/10.1016\/j.prnil.2020.12.003.","DOI":"10.1016\/j.prnil.2020.12.003"},{"key":"10.1016\/j.euf.2021.04.003_bib0070","series-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer","author":"Mottet","year":"2020"},{"key":"10.1016\/j.euf.2021.04.003_bib0075","series-title":"Prostate cancer, version 1.2020, NCCN clinical practice guidelines in oncology","author":"Mohler","year":"2020"},{"key":"10.1016\/j.euf.2021.04.003_bib0080","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2021.04.003_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2021.04.003_bib0095","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0100","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7 Suppl","key":"10.1016\/j.euf.2021.04.003_bib0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2019.37.7_suppl.141","article-title":"Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-na\u00efve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT)","volume":"37","author":"Fizazi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.euf.2021.04.003_bib0115","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/j.annonc.2020.08.871","article-title":"611O Abiraterone acetate plus prednisolone for hormone-na\u00efve prostate cancer (PCa): long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)","volume":"31","author":"James","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0120","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0125","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.04.003_bib0130","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u2018high-\u2019 and \u2018low-risk\u2019 metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.04.003_bib0135","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2021.04.003_bib0140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2021.04.003_bib0145","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2021.04.003_bib0150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.euf.2021.04.003_bib0155","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.euf.2021.04.003_bib0160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euf.2021.04.003_bib0165","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","article-title":"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Mori","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euf.2021.04.003_bib0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euf.2021.04.003_bib0180","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/sim.8013","article-title":"One-sample aggregate data meta-analysis of medians","volume":"38","author":"McGrath","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2021.04.003_bib0185","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2021.04.003_bib0190","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2021.04.003_bib0195","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2021.04.003_bib0200","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2021.04.003_bib0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bju.12898","article-title":"Enzalutamide in European and North American men participating in the AFFIRM trial","volume":"115","author":"Merseburger","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.04.003_bib0210","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/j.1464-410X.2008.07519.x","article-title":"Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer","volume":"101","author":"Gallina","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.04.003_bib0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5489\/cuaj.5187","article-title":"Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: a comprehensive analysis of the literature and meta-analysis of randomized controlled trials","volume":"12","author":"Karakiewicz","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euf.2021.04.003_bib0220","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2016.11.034","article-title":"Updated European Association of Urology guidelines regarding adjuvant therapy for renal cell carcinoma","volume":"71","author":"Bex","year":"2017","journal-title":"Eur Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:51:48Z","timestamp":1762498308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456921001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2405456921001097"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2021.04.003","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}